Conclusion
The availability of a biomarker that predicts the AIT outcome would be extremely useful in clinical practice, but it should be reliable and easily achievable. Serum-sIgE assay is a popular test, commonly used by the allergist. Moreover, positive IgE is a typical marker for the allergic phenotype and high serum-sIgE levels may be associated with symptom severity.[14]
The present study also confirms that the sIgE levels in allergic children may be associated with AIT response. In other words, a sIgE level >10 kU/l before AIT prescription could advise the allergist that AIT might have a good chance of efficacy.
In conclusion, allergen-sIgE assessment before AIT prescription might represent a useful tool to individuate potential responders.
Immunotherapy. 2014;6(1):29-33. © 2014 Future Medicine Ltd.
